In short
Quizartinib Dihydrochloride, also known as Quizartinib, is a drug currently being studied in clinical trials for the treatment of acute myeloid leukemia (AML), particularly in patients with FLT3-ITD mutations. This article explores the ongoing research and potential benefits of Quizartinib in treating this aggressive form of blood cancer.
At a glance
- Drug Name
- Quizartinib Dihydrochloride (Quizartinib)
- Target Condition
- Acute Myeloid Leukemia (AML) with FLT3-ITD mutations
- Administration
- Oral tablets, once daily
- Clinical Trial Phase
- Expanded Access Program and Bioavailability Study
- Key Features
- Selective FLT3 inhibitor, potential treatment for relapsed/refractory AML
- Regulatory Status
- Fast Track Status (US), Orphan Drug Indication (US, Europe, Asia)
- Ongoing Research
- Efficacy, safety, pharmacokinetics, bioavailability
What is Quizartinib?
Quizartinib Dihydrochloride, also known simply as Quizartinib, is a medication being developed to treat certain types of blood cancers. It is classified as a selective FLT3 inhibitor, which means it targets a specific protein that is often involved in the growth of cancer cells.
What Condition Does Quizartinib Treat?
Quizartinib is primarily being developed to treat Acute Myeloid Leukemia (AML) with specific genetic mutations. AML is a type of cancer that affects the blood and bone marrow, causing rapid growth of abnormal white blood cells. Specifically, Quizartinib targets AML with FLT3-ITD mutations. This means it's designed for patients whose leukemia cells have a particular genetic change in the FLT3 gene.
The drug is being studied for use in cases where: The leukemia has come back after previous treatment (relapsed AML) The leukemia has not responded well to other therapies (refractory AML)
Additionally, research suggests that Quizartinib may also have potential in treating myelodysplastic syndrome (MDS), another type of blood disorder.
How Does Quizartinib Work?
Quizartinib works by targeting and inhibiting the FLT3 protein, which is often overactive in AML cells with the FLT3-ITD mutation. By blocking this protein, Quizartinib may help to slow down or stop the growth of these cancer cells.
How is Quizartinib Administered?
Quizartinib is taken orally in the form of tablets. In clinical trials, it is typically administered once daily in continuous 28-day cycles. The exact dosage is determined by the treating physician based on individual patient factors.
Current Clinical Trials
Quizartinib is currently undergoing various clinical trials to evaluate its effectiveness and safety. It has been granted Fast Track Status in the US and an Orphan Drug Indication in the United States, Europe, and Asia, which highlights its potential importance in treating AML.
Expanded Access Program
An Expanded Access Program (EAP) is available for Quizartinib in several countries. This program allows doctors to give the medicine to eligible patients before it receives full approval from health authorities. The EAP for Quizartinib includes the following key points:
- It's available for adult patients with relapsed or refractory FLT3-ITD mutated AML
- Patients can receive Quizartinib if their doctor submits a request and they meet eligibility criteria
- Treatment can continue until there's a lack of clinical benefit or unacceptable side effects occur
- The program is available in several countries including parts of Europe, Asia, and the United States
Bioavailability Study
A recent study was conducted to determine the absolute oral bioavailability of Quizartinib. Bioavailability refers to how much of a drug enters the bloodstream and is available to have an active effect. This study involved:
- Healthy male subjects
- Administration of both oral and intravenous (IV) Quizartinib
- Detailed measurements of drug concentrations in the blood over time
- Assessment of safety and tolerability
This type of study helps researchers understand how the body processes Quizartinib, which is crucial for determining the most effective dosing strategies.